@article{3b0ac290c969469abf7cfb3460d25ea9,
title = "Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results",
abstract = "Purpose: In oropharyngeal squamous cell carcinoma (OPC), high CD8{\th} tumor-infiltrating lymphocyte (CD8{\th}TIL) density confers improved prognosis. We compared neoadjuvant durvalumab (PD-L1 inhibitor) with durvalumab {\th} tremelimumab (CTLA-4 inhibitor) in terms of impact on CD8{\th}TIL density, safety, and efficacy in patients with OPC. Patients and Methods: Patients with newly diagnosed stage II-IVA OPC or locoregionally recurrent OPC amenable to resection were included. Patients were randomized to two cycles of durvalumab or durvalumab {\th} tremelimumab before surgery. The primary endpoint was change between baseline and resection specimen in CD8{\th}TIL density between arms. Secondary endpoints included safety, response rate per RECIST, major pathologic response (MPR; ≤10% viable tumor cells) rate, and patient-reported outcomes. Results: Of 28 eligible patients (14/arm), 20 (71%) had newly diagnosed OPC, and 24 (86%) were p16-positive. The posttreatment to pretreatment median CD8{\th}TIL density ratio was 1.31 for durvalumab and 1.15 for combination treatment (P ¼ 0.97; 95% CI: -1.07-2.28). In each group, 6 patients (43%, 95% CI: 17.66-71.14) had a response. Eight patients (29%) had a MPR at the primary tumor and/or nodal metastases. Neither baseline CD8{\th}TIL density nor PD-L1 expression level correlated with overall response, but a trend toward greater CD8{\th}TIL change in patients with a MPR was seen (P ¼ 0.059; 95% CI: -0.33-3.46). Four patients (14%) had grade ≥3 adverse events. At median follow-up time of 15.79 months, all patients were alive, and one had an additional recurrence. Conclusions: Durvalumab {\th} tremelimumab did not increase CD8{\th}TIL density more than durvalumab alone did. The observed safety and activity support further investigation of neoadjuvant checkpoint inhibitor for OPC.",
author = "Renata Ferrarotto and Diana Bell and Rubin, {Maria L.} and Hutcheson, {Katherine A.} and Johnson, {Jason M.} and Goepfert, {Ryan P.} and Jack Phan and Elamin, {Yasir Y.} and Torman, {Danice K.} and Warneke, {Carla L.} and Hessel, {Amy C.} and Garden, {Adam S.} and Myers, {Jeffrey N.} and Johnson, {Faye M.} and {Jack Lee}, J. and Sikora, {Andrew G.} and Gillison, {Maura L.} and Glisson, {Bonnie S} and Gross, {Neil D.}",
note = "Funding Information: The authors thank Stephanie P. Deming for editorial assistance. R Ferarotto was generously supported by Mr. & Mrs. Charles W. Stiefel (financial support for clinical trial personnel) of The University of Texas MD Anderson Cancer Center-Oropharynx Cancer Program, NCI grant P30CA016672 (financial support for clinical trial conduct and core facilities for biomarker analysis), and Astra Zeneca (provided investigational agent and financial support for collection and storage of biospeci-mens). K Hutchetson was supported by NRG pilot award UG1CA189867 (financial support for patient-reported outcomes questionnaires administration). Funding Information: American Speech Language Hearing Association. J.M. Johnson is an employee/ paid consultant for Kura Oncology, and reports receiving commercial research grants from Blue Earth Diagnostics. F.M. Johnson reports receiving commercial research grants from PIQUR Therapeutics and Trovagene. A. Sikora reports receiving commercial research grants from Tessa Therapeutics, SQZ and Heat/Pelican. M.L. Gillison is an employee/paid consultant for EMD Serono, AstraZeneca, Amgen, TRM Oncology, NewLink, Shattuck Labs, Merck, BMS, Roche, Bayer, Genocea, and Aspyrian, and reports receiving commercial research grants from Genocea, BMS, and Cullinan. N.D. Gross is an employee/paid consultant for PDS Biotechnology, Shattuck Labs, Genzyme, and Intuitive Surgical, and reports receiving commercial research grants from Regeneron. No potential conflicts of interest were disclosed by the other authors. Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",
year = "2020",
month = jul,
doi = "10.1158/1078-0432.CCR-19-3977",
language = "English (US)",
volume = "26",
pages = "3211--3219",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",
}